icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetic (PK) Drug-Drug Interaction between Samatasvir (IDX719), a Pan-Genotypic NS5A Inhibitor, and Simeprevir in Healthy Volunteers and HCV-Infected Subjects
 
 
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
 
X.J. Zhou1, E. Donovan1, J. Chen1, D. Frank1, R. van Heeswijk2, J. Z. Sullivan-Bólyai1, P. Van Remoortere3, R. Verloes2, G. Picchio3, D. Mayers1 and the HELIX-1 Investigator Group
1 Idenix Pharmaceuticals, Inc., Cambridge, MA; 2Janssen Infectious diseases BVBA, Beerse, Belgium; 3 Janssen Research and Development, Titusville, NJ
 
IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected
Subjects.....http://www.natap.org/2013/HCV/013113_03.htm
 
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C (April 7, 2014).......http://www.natap.org/2014/HCV/040714_01.htm
 
HELIX-2, a phase II all-oral combination study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the treatment of hepatitis C has been initiated (12/03/2013).....http://www.natap.org/2013/HCV/120313_02.htm
 

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif

CROI10.gif

CROI11.gif

CROI12.gif

CROI13.gif

CROI14.gif